Sales projections: What is the expected Lipitor revenue path over 5-10 years under generic price compression? Featured snippet answer: Lipitor sales over the next decade are expected to track a declining brand share multiplied by net price that continues to compress toward generic equivalents, while total atorvastatin class demand is broadly … Pfizer is once again confronting a major patent cliff, similar to the one it faced in the early 2010s when it lost exclusivity on several high-revenue drugs including Lipitor, Protonix, and Geodon. During that period, Lipitor's annual sales declined significantly from a peak of $12.9 billion following the entry of generic competitors. Humira, introduced by AbbVie in 2003, is expected to remain the drug with the highest lifetime revenue through 2024. Keytruda follows with a lifetime revenue of 213 billion U.S. dollars. Pfizer Annual Reports & Investor Presentations – The company discloses annual revenue figures for its major product lines, including atorvastatin. – In 2005‑2008, the reported sales for Lipitor hovered around the $12-13 bn mark. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident … Investor Relations Quarterly Results Select a year: 2. Lipitor's Commercial and IP Architecture Atorvastatin calcium, marketed as Lipitor by Pfizer, received FDA approval in January 1997. It is a synthetic HMG-CoA reductase inhibitor that produces greater LDL-C reductions at equivalent doses than any statin that preceded it. By the time the primary compound patent expired in November 2011, the drug had generated cumulative worldwide sales … China LIPITOR Market Trends China's LIPITOR market is witnessing rapid growth driven by escalating cardiovascular disease incidence and governmental healthcare reforms aimed at universal drug access. Policies encouraging generic drug use and faster regulatory approvals have expanded market options beyond Pfizer's original formulation. "We believe we have a clear strategy, scientific leadership and strong capabilities that position us to create sustained, long-term value for shareholders and positive impact for the patients and others we're privileged to serve." Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago. The big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic … Health, Pharma & Medtech Pharmaceutical Products & Market Worldwide revenue of Pfizer's Lipitor from 2003 to 2019 (in million U.S. dollars) Indeed, Pfizer's business model has relied on the huge profits from Lipitor and a few other blockbuster drugs. But things are set to change. The patent for Lipitor expired on Nov 30. Pfizer will undoubtedly feel the loss of Lipitor sales. It has been planning for this schismatic change for several years. Counting up 25 years' worth of sales, Pfizer's Lipitor remains the U.S.' best-selling drug over the past two and a half decades, but AbbVie's Humira will soon catch up. (Pixabay/CC0) Take a look … A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 1/2 years. That isn't a typo—sales of Lipitor topped $5 billion dollars in 2010 alone. And for Pfizer, the maker of the powerful cholesterol drug, this month was marked on their calendars for years. This is a critical time for them. Lipitor has helped pad Pfizer's earnings numbers for years. We would like to show you a description here but the site won't allow us. During the past decade Pfizer's (PFE) Lipitor generated $115 billion in cumulative global revenue. With a $93 million settlement, Pfizer can wash its hands of more than a decade's worth of antitrust litigation over the once-lucrative cholesterol med Lipitor. Atorvastatin is a statin medication used to lower cholesterol levels in the blood. It was originally developed by Pfizer and is commonly sold under the brand name Lipitor. Lipitor redefined the statin category, achieved record prescription volumes, and set a durable benchmark for cardiovascular brand leadership after its 1997 launch. Pfizer, founded in 1849, combined scientific strength and disciplined commercialization to build the world's most recognized cholesterol brand. Marketing strategy amplified clinical differentiation, simplified risk communication … A version of this article appears in print on May 2, 2012, Section B, Page 1 of the New York edition with the headline: Pfizer Profit Declines 19% On Slumping Lipitor Sales. LIPITOR is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. Assessing the industry's biggest ever products by lifetime sales, rather than peak annual performance, further confirms the status of Pfizer's Lipitor as the most commercially successful drug of all time. Over the course of its lifetime, Lipitor has generated global sales of $141 billion – nearly double that of its closest competitor in the list, Bristol-Myers Squibb and Sanofi's Plavix … Lipitor (atorvastatin) was discovered at Parke-Davis and launched in 1997, the fifth statin on the market. It became the world's best-selling drug, with sales peaking at US$12.9 billion in 2006, until Humira overtook its lifetime sales in 2020. We would like to show you a description here but the site won't allow us. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. By 2015, if all Pfizer's marketing and distribution plans fall into place, the company should have a $3 billion blockbuster drug on its hands, bolstering its sales and bottom line at a time when … Pfizer reported a 14% drop in quarterly earnings as sales slumped for Lipitor after the former blockbuster cholesterol drug lost U.S. market exclusivity. Pfizer's top product based on revenue is COVID-19 vaccine Comirnaty, generating almost 38 million U.S. dollars in 2022. Lipitor's patent cliff — how the world's best-selling drug lost everything overnight Lipitor generated over $125 billion during its patent window. Then a calendar date arrived. Here is what Pfizer did before, during, and after — and what the playbook teaches about how pharma manages the most predictable crisis in the industry. En Afanias trabajamos para prestar apoyo a las personas con discapacidad y a sus familias, proporcionando recursos y acompañamiento. 172 TOTTENHAM COURT RD LONDON W1T 7NS +44 20 3696 7500 Teva Sector P&L Price Performance R&D Valuation Summary Summary Sheet close Valuation Metrics Account Change Password Email Preferences Other Shareprice Summary Reporting Heatmap Share Price Movers Single Drug Snapshot Custom Models DA STAFF PORTFOLIOS close { {drug.companyName}} { {drug.drugName}} Chart Sales Snapshot QoQ T&Ds First … Annual Sales of Lipitor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. The sales force further supported the Lipitor campaign through the distribution of free product samples. Warner-Lambert and Pfizer implemented an aggressive sampling program, distributing 7.3 million samples to physicians in the first year of launch for a share of voice of slightly over 23%. [49] Lipitor Success Lipitor is a blockbuster. Warner-Lambert and Pfizer have bragging rights to one of … The hypercholesterolemia segment held the largest share of the global Atorvastatin Calcium market in 2025, capturing 45.9% of total revenue. The increasing prevalence of elevated cholesterol levels, driven by sedentary lifestyles, obesity, unhealthy dietary habits, and aging populations, has significantly contributed to the segment's leadership. Over 14.5 years, the cholesterol-lowering medicine has made over $125 billion in sales, and has provided up to a quarter of Pfizer Inc.'s annual revenue for years. It may take a breakthrough treatment for Alzheimer's disease to match the $130 billion lifetime sales record of Pfizer's Lipitor, the cholesterol fighter that wrote its own chapter in … But its sales fell 10%. How so? Pfizer's sale of the nutrition business, which went to Nestle for $11.85 billion, helped boost reported net income to $14.57 billion. Pfizer Inc., the world's biggest drugmaker, is not giving up that easy on the best-selling drug in history. Lipitor had peak sales of about $13 billion and still brings in nearly $11 billion a year, about a sixth of Pfizer's revenue. With no new blockbusters to fill that hole, the company is making an unprecedented push to hang onto Lipitor revenue as long as possible.